Table 1 Patient Characteristics with Increasing Total Social Vulnerability.
From: Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US
Characteristic | N | Total SVI Score | ||||
|---|---|---|---|---|---|---|
0.000–0.199, N = 13314 (18%) | 0.200–0.399, N = 15626 (21%) | 0.400–0.599, N = 12721 (17%) | 0.600–0.799, N = 17209 (23%) | 0.800–0.999, N = 15625 (21%) | ||
Age | 74,495 | |||||
20-44 years | 467 (3.5%) | 595 (3.8%) | 465 (3.7%) | 685 (4.0%) | 482 (3.1%) | |
45-64 years | 6066 (46%) | 7124 (46%) | 5673 (45%) | 8405 (49%) | 7122 (46%) | |
65-84 years | 6257 (47%) | 7378 (47%) | 6044 (48%) | 7539 (44%) | 7433 (48%) | |
85+ years | 524 (3.9%) | 529 (3.4%) | 539 (4.2%) | 580 (3.4%) | 588 (3.8%) | |
Sex | 74,495 | |||||
Male | 10,711 (80%) | 12,597 (81%) | 10,409 (82%) | 13,752 (80%) | 12,645 (81%) | |
Female | 2603 (20%) | 3029 (19%) | 2312 (18%) | 3457 (20%) | 2980 (19%) | |
Race | 74,495 | |||||
White | 12,178 (91%) | 13,101 (84%) | 9225 (73%) | 11,731 (68%) | 10,371 (66%) | |
Black | 625 (4.7%) | 1669 (11%) | 1526 (12%) | 4198 (24%) | 2609 (17%) | |
Hispanic | 352 (2.6%) | 520 (3.3%) | 860 (6.8%) | 833 (4.8%) | 2058 (13%) | |
Asian or Pacific Islander | 101 (0.8%) | 258 (1.7%) | 1,019 (8.0%) | 341 (2.0%) | 482 (3.1%) | |
Native American | 24 (0.2%) | 44 (0.3%) | 46 (0.4%) | 65 (0.4%) | 51 (0.3%) | |
Unknown | 34 (0.3%) | 34 (0.2%) | 45 (0.4%) | 41 (0.2%) | 54 (0.3%) | |
Region | 74,495 | |||||
Midwest | 4274 (32%) | 3562 (23%) | 705 (5.5%) | 5,940 (35%) | 90 (0.6%) | |
Northeast | 5694 (43%) | 4562 (29%) | 763 (6.0%) | 1,053 (6.1%) | 497 (3.2%) | |
South | 1633 (12%) | 2549 (16%) | 2257 (18%) | 5226 (30%) | 5481 (35%) | |
West | 1713 (13%) | 4953 (32%) | 8996 (71%) | 4990 (29%) | 9557 (61%) | |
Primary Site | 74,495 | |||||
Larynx Glottic | 7200 (54%) | 8363 (54%) | 7126 (56%) | 8781 (51%) | 8309 (53%) | |
Larynx Other | 1364 (10%) | 1613 (10%) | 1144 (9.0%) | 2035 (12%) | 1,759 (11%) | |
Larynx Subglottic | 204 (1.5%) | 221 (1.4%) | 184 (1.4%) | 253 (1.5%) | 267 (1.7%) | |
Larynx Supraglottic | 4546 (34%) | 5429 (35%) | 4267 (34%) | 6140 (36%) | 5290 (34%) | |
TNM/AJCC Combined Stage | 71,572 | |||||
Stage I-III | 10,561 (84%) | 12,689 (84%) | 10,059 (82%) | 13,093 (79%) | 11,544 (77%) | |
Stage IV & Above | 2069 (16%) | 2332 (16%) | 2199 (18%) | 3519 (21%) | 3507 (23%) | |
SEER-desginated Grade | 58,748 | |||||
Grade I or II | 8082 (77%) | 9425 (78%) | 7725 (77%) | 10,114 (76%) | 9761 (76%) | |
Grade III or above | 2410 (23%) | 2701 (22%) | 2341 (23%) | 3186 (24%) | 3003 (24%) | |
Primary Surgery Performed | 72,640 | |||||
No Surgery | 6,446 (51%) | 7479 (50%) | 6984 (56%) | 9386 (55%) | 9142 (59%) | |
Surgery | 6,285 (49%) | 7448 (50%) | 5597 (44%) | 7596 (45%) | 6277 (41%) | |
Radiation Therapy Performed | 74,495 | |||||
No Therapy | 3694 (28%) | 4005 (26%) | 3112 (24%) | 4707 (27%) | 4513 (29%) | |
Therapy | 9620 (72%) | 11,621 (74%) | 9609 (76%) | 12,502 (73%) | 11,112 (71%) | |
Chemotherapy Performed | 74,495 | |||||
No Therapy | 10,701 (80%) | 12,805 (82%) | 10,279 (81%) | 12,972 (75%) | 11,689 (75%) | |
Therapy | 2613 (20%) | 2821 (18%) | 2442 (19%) | 4237 (25%) | 3936 (25%) | |
Vital Status on Last Follow-up | 74,495 | |||||
Alive | 3989 (30%) | 3795 (24%) | 3767 (30%) | 5348 (31%) | 5465 (35%) | |
Dead | 9325 (70%) | 11,831 (76%) | 8954 (70%) | 11,861 (69%) | 10,160 (65%) | |
